BRIEF: 111 Inc.’s revenue drops in second quarter
Drug seller 111 Inc. (YI.US) said on Wednesday its revenue fell 6.4% year-on-year to 3.2 billion yuan ($450 million) in the second quarter, as revenue for its core business of…
FAST NEWS: 111 Inc. enters strategic supply agreement with Scrianen Pharma
The Latest: Pharmaceutical distributor 111 Inc. (YI.US) announced Tuesday that it has entered into a strategic direct supply partnership with drug developer and maker Beijing Scrianen Pharmaceutical. Looking Up: This…
FAST NEWS: 111 Inc’s Revenue Flattens on Covid Disruptions
The Latest: Online drug seller 111 Inc. (YI.US) on Thursday reported third-quarter revenue of 3.35 billion yuan ($470.8 million), roughly the same as a year earlier. Its net loss for…
Share Buybacks Bring Mixed Results for Smart Share Global, Cloopen
Two China tech firms are the latest in a recent string to announce share repurchases with hopes of boosting their sagging stocks Key points: Smart Share Global’s shares surged after…
Solid Earnings, Modest Buyback Fail to Boost Drug Seller 111 Inc.
Profitability is now in focus at online drug company, as it seeks to breathe life into its shares that are down 10% this year Key takeaways: 111’s revenue grew 87%…
Recent Articles
RELATED ARTICLES
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK -
BRIEF: Sands China second-quarter profit drops 13%
1928.HK
-
Second-quarter box office blues dampen diversifying Maoyan
1896.HK
-
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
LEGN.US
-
BRIEF: NetEase revenue, profit rise in second quarter
9999.HK NTES.US
- RNA drug developer Ribo Life targets fresh funding channel
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
